-+ 0.00%
-+ 0.00%
-+ 0.00%

Liminatus Pharma Entered Definitive Agreement To Acquire InnocsAI On May 17 In $320M All-Stock Transaction

Benzinga·05/21/2026 12:07:44
Listen to the news

The proposed merger has been approved by the boards of directors/managers of both companies and remains subject to customary closing conditions, including shareholder approval, regulatory approvals and other conditions set forth in the Merger Agreement.

Additional information regarding the transaction will be included in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.